Ken Griffin 180 Life Sciences Corp. Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.12 - $1.31 $1,170 - $12,780	9,756 Added 19.14%	60,717 $41,000
Q2 2022 Aug 15, 2022	BUY	$0.81 - $2.53 $16,150 - $50,445	19,939 Added 64.27%	50,961 $43,000
Q1 2022 May 16, 2022	SELL	$2.53 - $3.9 $153,877 - $237,201	-60,821 Reduced 66.22%	31,022 $80,000
Q4 2021 Feb 14, 2022	SELL	$3.27 - $6.38 $33,344 - $65,056	-10,197 Reduced 9.99%	91,843 $358,000
Q3 2021 Nov 15, 2021	BUY	$5.11 - $10.81 $135,767 - $287,210	26,569 Added 35.2%	102,040 $552,000
Q2 2021 Aug 16, 2021	BUY	$6.7 - $11.98 $315,188 - $563,575	47,043 Added 165.48%	75,471 $754,000
Q1 2021 May 17, 2021	BUY	$2.51 - $6.96 $695 - $1,927	277 Added 0.98%	28,428 $186,000
Q4 2020 Feb 16, 2021	BUY	$2.15 - $11.17 $60,524 - $314,446	28,151 New	28,151 $77,000

Ticker ATNF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,698,900
Market Cap $81.1M
Description
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on f...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.